Literature DB >> 12405078

Insight and personal narratives of illness in schizophrenia.

Paul H Lysaker1, Catherine A Clements, Cynthia D Plascak-Hallberg, Stacy J Knipscheer, Dustin E Wright.   

Abstract

Insight in schizophrenia tends to be assessed as the degree to which one possesses specific knowledge. It therefore often fails to account for the fact that awareness of illness is an inextricable part of a personal narrative and may be incoherent or incomplete for many different narrative reasons. Accordingly, we have developed a means of eliciting narratives of illness: the Indiana Psychiatric Illness Interview, and a method for rating the coherence of those narratives: the Narrative Coherence Rating Scale. In this article we describe these methods and present data on their reliability and validity in a study of the illness narratives of 33 outpatients with schizophrenia or schizoaffective disorder. Results suggest our measures possess sufficient internal consistency and good to excellent interrater reliability. Additionally, as predicted, our measures of narrative coherence were significantly correlated with traditional measures of insight and with measures of cognitive impairment and hopelessness gathered earlier.

Entities:  

Mesh:

Year:  2002        PMID: 12405078     DOI: 10.1521/psyc.65.3.197.20174

Source DB:  PubMed          Journal:  Psychiatry        ISSN: 0033-2747            Impact factor:   2.458


  41 in total

1.  Values in persons with schizophrenia.

Authors:  Giovanni Stanghellini; Massimo Ballerini
Journal:  Schizophr Bull       Date:  2006-08-29       Impact factor: 9.306

2.  A randomized-controlled trial of treatment for self-stigma among persons diagnosed with schizophrenia-spectrum disorders.

Authors:  Philip T Yanos; Paul H Lysaker; Steven M Silverstein; Beth Vayshenker; Lauren Gonzales; Michelle L West; David Roe
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-04-01       Impact factor: 4.328

3.  Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness.

Authors:  Piotr J Quee; Lisette van der Meer; Richard Bruggeman; Lieuwe de Haan; Lydia Krabbendam; Wiepke Cahn; Niels C L Mulder; Durk Wiersma; André Aleman
Journal:  Schizophr Bull       Date:  2010-11-22       Impact factor: 9.306

4.  The relationship between consumer insight and provider-consumer agreement regarding consumer's quality of life.

Authors:  Ilanit Hasson-Ohayon; David Roe; Shlomo Kravetz; Itamar Levy-Frank; Taly Meir
Journal:  Community Ment Health J       Date:  2011-01-14

5.  Metacognitive capacities for reflection in schizophrenia: implications for developing treatments.

Authors:  Paul H Lysaker; Giancarlo Dimaggio
Journal:  Schizophr Bull       Date:  2014-03-17       Impact factor: 9.306

6.  Narrative enhancement and cognitive therapy (NECT) effectiveness: a quasi-experimental study.

Authors:  David Roe; Ilanit Hasson-Ohayon; Michal Mashiach-Eizenberg; Oren Derhy; Paul H Lysaker; Philip T Yanos
Journal:  J Clin Psychol       Date:  2013-10-02

7.  Narrative enhancement and cognitive therapy: a new group-based treatment for internalized stigma among persons with severe mental illness.

Authors:  Philip T Yanos; David Roe; Paul H Lysaker
Journal:  Int J Group Psychother       Date:  2011-10

8.  The Role of Insight in Moderating the Association Between Depressive Symptoms in People With Schizophrenia and Stigma Among Their Nearest Relatives: A Pilot Study.

Authors:  Dzmitry Krupchanka; Mikhail Katliar
Journal:  Schizophr Bull       Date:  2016-03-12       Impact factor: 9.306

9.  The Role of Metacognitive Self-Reflectivity in Emotional Awareness and Subjective Indices of Recovery in Schizophrenia.

Authors:  Kelsey A Bonfils; Lauren Luther; Sunita George; Kelly D Buck; Paul H Lysaker
Journal:  J Nerv Ment Dis       Date:  2016-12       Impact factor: 2.254

10.  Metacognition, Personal Distress, and Performance-Based Empathy in Schizophrenia.

Authors:  Kelsey A Bonfils; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.